Scottsdale Prostate Cancer Symposium Archives

Neoadjuvant Therapy for High-Risk Prostate Cancer

Posted by Adam S. Kibel, MD | Aug 2019

Adam S. Kibel, MD, argues that, while it is common to debate the best intervention method for local prostate cancer, there also must be an emphasis on the systemic treatment of micro-metastatic disease in the interest of decreasing disease-specific death. He then reviews the impact of timing, duration, and intensity of systemic therapy on patient outcomes, focusing on four trials evaluating neoadjuvant therapy for high-risk prostate cancer.

Advanced PET Imaging for Prostate Cancer Staging

Posted by Nelson N. Stone, MD | Aug 2019

Nelson N. Stone, MD, discusses the importance of precisely locating sites of failure in recurrent prostate cancer patients. He focuses on how new positron emission tomography (PET)/CT imaging agents can improve detection, noting the need for improved detection methods in patients with low PSA levels.

The Modern Definition of Successful Cancer Treatment – Cure with Quality of Life

Posted by Patrick W. McLaughlin, MD | Aug 2019

Patrick W. McLaughlin, MD, discusses the balance of cure versus quality-of-life when treating prostate cancer patients. He details his approach to ensuring optimal patient-preferred outcomes using physician-as-advocate decision-making, as well as individual anatomical and tumor characteristics in guiding treatment planning.

The Staggering Benefit of PSA Screening in Potentially Lethal Prostate Cancer

Posted by Patrick W. McLaughlin, MD | Jul 2019

Patrick W. McLaughlin, MD, discusses the limitations of evidence that provide the basis for the United States Preventive Services Task Force’s (USPSTF’s) negative gradings for PSA screening. He argues that in the modern era, with the currently-available curative therapy for most lethal prostate cancers, intensive screening can allow early enough detection to provide patients opportunities for a cure.

Temporal Shifts in Grade and Stage of Prostate Cancer: A Whole Mount Analysis

Posted by M. Scott Lucia, MD | Jul 2019

M. Scott Lucia, MD, discusses the impact of changes in the clinical management of prostate cancer on pathological features of tumors in prostatectomy specimens processed over the last 16 years at his institution. He discusses the role of shifting screening and active surveillance practices in these observed changes in tumor features.